Treatment of Severe Falciparum Malaria With Artemisinin and Exchange Transfusion Case Report

Elfadil Mohamed Osman

Almana Hospital P.O.Box 2366 Dammam 31451 Saudi Arabia

Abstract:

In this communication a young patient presented with severe Falciparum Malaria with multiple organ involvement. He did not respond to conventional anti-malarial treatment e.g. Chloroquine, Quinine in full conrses, However he showed remarkable improvement and finally cured after treatment with exchange transfusion and Artemisinin,

Introduction:

Malaria associated with complications or fatal outcome is almost always caused by Plasmodium Falciparum. The mortality due to this disease parallels the degree of Parasitemia. Successful use of exchange transfusion as a therapeutic adjunct for this infection was first reported in 1974, although the efficacy of this procedure has not been established by randomized, controlled trials.

The rationale for this form of therapy is based on: rapid reduction in the parasite load by direct removal, decrease risk of severe intravascular haemolysis and its consequences (disseminated intravascular coagulation and renal dysfunction), improve rheology with transfused blood, reduce micro-circulatory sludging and improved oxygen-carrying capacity with transfused erythrocytes.

Artemisinin or Qinghaosu - Artemesia annua (Sweet wormwood) is found in many parts of the world. In the early 1970's Chinese scientist recognized its potential for treating malaria and isolated the active principle artemisinia or ginghaosu. To combat increasing problems with drug resistance to Plasmodium Falciparum, Vietnam has turned increasingly to artemisinia derivatives. Oral and suppository formulations are produced from locally grown plants. These compounds have been rapidly effective in the treatment of malaria in a large number of studies. (2)

Case Report:

A previously healthy 39 years male Filipino was admitted to the hospital with a 4 days history of fever, chills, backache, vomiting and diarrhea. He had recently been to Najran area 10 days before admission. He was treated with Chloroquine full course before coming to our hospital.

On admission, the patient was ill, pale, temperature 39°C, pulse 116 per minute, blood pressure 110/80 mmHg, respiratory rate 30 per minute. He had jaundice. His heart, chest were normal. In the abdomen the spleen and liver were not palpable. He was alert, oriented and there were no neurologic deficits.

His initial investigations were as follows: HB 13.7g/dl (13.5-18), WBC 3100 (4-11), platelets 70,000 (150-400,000), Reticulocytes 0.9%, ESR 30mm in the first hour. Blood film showed normocytic normochromic red cells, studded with ring forms of plasmodium falciparum. (No parasite count was done) LDH 560 (31.3-618), blood sugar 6.1 mmol/L (3.6-6.8), creatinine 111 umol/L, (70-133) BUN 5.9 mmol/L, (2.5-7.5) Albumin 36 gram/L, (39-50) SGOT 102 U/L, (50-57) SGPT 71 U/L, (5-56) GGT 162 U/Lm, (8-78) total bilirubin 27 umol/L. His urine and stool analysis were normal. Blood, urine and stool cultures were all negative. He was treated with oral chloroquine sulphate in a dose of 600 mg initially, followed by 300mg single dose after 8 hours, then 300 mg daily for 2 days. He continued to have fever and positive blood films. Oral Quinine sulphate in a dose of 600mg TID with Doxycycline 100mg BID was started for 10 days.(I.V. Quinine was not available)

The patient continued to deteriorate inspite Quinine Sulphate, Doxycycline therapy which was later changed to intravenous Clindamycin 600 mg 8 hourly on day 7. He became more ill, continued to have high grade fever, 39-41oC, dyspnoea, his chest was full of crepitations and his chest x-ray showed features of pulmonary oedema, inspite adequate fluid balance and urine output. This was thought to be due to capillary leak syndrome. His haemoglobin and platelets started to drop (Table 1). LDH increased as well as unconjugated bilirubin.

His blood film showed fragmented red cells and polkiloanisocytosis and was full of parasites. He continued on Quinine and Clindamycin for 10 days. Twelve days after admission, exchange transfusions were started and he was given Artemisinin 3.2mg per kg body weight intramuscularly (I.M),

followed by 1.6mg per kg. (I.M) every 24 hours for 5 days. ⁽⁸⁾ He was also treated with fluid restrictions and frusemide for his pulmonary oedema.

Four sessions of partial exchange transfusions was performed manually with saline replacement and 250 mls packed cells were transfused each session. Following the use of Artemisinin and exchange transfusion malaria parasites were cleared from the blood as checked by several blood films.

Two weeks after discharge from hospital, he was in good health, afebrile, his chest was clear. Hb was 14 grams, platelets normal and his blood film for malaria was negative.

Comments:

This case illustrates the beneficial effects of exchange transfusion as prompt reduction in parasitemia is required to halt the progression of pathophysiologic changes occurring in the microcirculation. (3) Exchange transfusion was first reported by Gyr et.al. (4) in 1974. Several reports since then were noted. (7) Data from these reports although obtained in uncontrolled trials, provide compelling evidence in the efficacy of this treatment modality for severe malaria. The use of exchange transfusion should be considered for the treatment of severe falciparum malaria in any of the following situations: parasitemia in >10% of circulating erythrocytes; cerebral malaria; disseminated intravascular coagulation and acute renal failure. (3)

In this patient Parasite count was not done before and after treatment with exchange transfusion and Artemisinin. ARTEMISININ or qinghaosu is the active principle of the Chinese medicine herb Artemisia annua & mdash; composite (sweet wormwood), which has been used as a treatment for fevers in China for more than 1000 years. Antimalarial activity resides in the endoperoxide structure. It destroys young trophozoites as well as other blood stages of P. Falciparum including chloroquine-resistant strains, and clears parasitaemia more rapidly than any other antimalarial drug. (5) Dihydroartemisinin, the active metabolite, is cleared rapidly. In China, clinical trials with intravenous artesunate (a water-soluble hemisuccinate), intramuscular artemether (the methyl ether suspended in peanut oil), and oral suppository preparations of artemisinin produced very encouraging results in the treatment of multiresistant P. Falciparum infections, suggesting perhaps a halving of mortality in cerebral malaria compared to quinine. (5) More recently, studies in Southeast Asia, Africa and South

America in cerebral and other severe forms of falciparum malaria have provided evidence of a rapid effect judged by fever and parasite clearance, suggestion of a reduction of mortality, and negligible toxicity. (9,10) The high recrudescence rates reported in earlier trials were attributed to inadequate dosage. In animal toxicity studies, there has been evidence of neurotoxicity, brainstem neuronal damage, and QT prolongation but these effects have not been seen in human patients. (6)

In conclusion, our patient with severe Falciparum Malaria resistant to multiple drugs responded very well to Artemisinin and exchange transfusion.

References

- 1. Trevertt A Lalloo D, "A New Look at an Old Drug: Artemesinin and Qinghaosu", Papua New Guinea Medical Journal 35(4) (Dec. 1992): 261-5
- 2. Hien TT, "An Overview of the Clinical Use of Artemisinin and Its Derivatives in The Treatment of Falciparum Malaria in Vietnam", Transactions of the Royal Society of Tropical Medicine and Hygiene Suppl 1 (Jun 1994): 57-8
- 3. Peter Phillips, Stephen Nantel and W. Barret Benny. Exchange Transfusions as an Adjunct to the Treatment of Severe Falciparum Malaria: Case Report and Review. Reviews of Infectious Diseases. Vol. 12, No. 6. Nov-Dec 1990
- 4. Gyr K, Speck B, Cornu P, Buckner CD. Zerebrate Malaria Tropica mit Schwarzeasserfieber. Ein Aktuelles Diagnostisches and Therapeutisches Problem. Schweiz Med Wochensch 1974; 104; 1628-30
- Bunnag D Kanda T Karbwang J Thimasam K Pungpak S Harinasuru T, "Artemethermefloquine combination in multi-drug resistant falciparum malaria, "Transactions of the Royal Society of Tropical Medicine and Hygiene 89 (20 Mar-April 1995): 213-5.
- 6. D.J. Weatherall, J.G. Ledingham, D.A. Warrell. Antimalarial Drugs Oxford Textbook of Medicine, Third Edition. Oxford University Press Inc., New York 1996: page 852
- 7. Wellcome Trust (1994). Artemisinin. Proceedings of a Meeting Convened by the Wellcome Trust on 25-27 April 1993. Transactions of the Royal Society of Tropical Medicine and Hygiene, 88 (Suppl.), S11-65
- 8. Nicholas J. White. Malaria, In Gordon Cook (ed). Manson's Tropical diseases London W.B. Saunders, 1996; 1088-1164
- Tran Tinh Hien, Nicholas P.J., Day, B.M. etal. A controlled trial of Artemether or Quinine in Vietnamese Adults with severe Falciparum Malaria. N Engl J Med. 1996; 335: 76-83
- Michael Boele Van Hensbroek, Emeka Onyiorah, Shabbar Jaffar, Gisela Schneider, etal. A trial of Artemether or Quinine in Children with Cerebral Malaria N Engl Med1996;335:69-75

TABLE (1)
Flowsheet of Patient Paratmenters During Stay in Hospital

Treatment		Quinine + Doxycycline							Exchange Transfusion + Artemisinin								
ГОН	n/L	3752	3582		3597	2995	2857								2029	1998	1700
Bil	UmoML	27	138	119	96	90	42	35	33	35	83	32	32	35	33	32	96
Alb	J/g	36	23	23	21	19	20	24	24	28	32	26	28	31	30	31	3.4
Ж	mmol/L	4.1		3.7	3.5	3.6	3.3	2.7	3.0	3.8	5.2	4.5	4.4	4.6	4.3	4.4	
Na	mmol/L	134		128	130	130	122	128	130	133	127	134	135	132	130	133	*33
Crea	Umol/L	111		183	170	101	89	90	78	79	128	73	92	87	77	70	î
Urea	mmol/L	5.9		14.4	6.5	7.0	3.4	2.7	3.1	3.5	20.6	5.7	5.2	3.6	2.9	3.0	
Plat	x109/L	70	38	35	37	19	78	252	72	88	84	06	90	115	125	128	021
WBC	х109лг	3.1	7.2	7.5	6.6	10.0	4.2	4.1	3.8	4.4	5.0	2.8	2.4	4.0	4.0	3.2	
НЬ	g/dL	13.7	8.6	6.6	10	8.2	10.2	13.5	10.3	6.11	9.11	10.9	10.7	11.1	10.4	7.6	
		8661-10-90	10-01-1998	11-01-1998	12-01-1998	14-01-1998	15-01-1998	16-01-1998	17-01-1998	18-01-1998	19-01-1998	20-01-1998	21-01-1998	22-01-1998	23-01-1998	24-01-1998	0001 10 36

()

مستفشيات المانع العامة ص.ب ٢٣٦٦ الدمام ٣١٤٥١ الملكة العربية السعودية

:

فيما يتصل بهذا الموضوع فإن مريض شاب كان قد حضر يعاني من ملاريا فالسيبارم حادة مع تأثيرها على أعضاء مختلفة لم يستجب للعلاج بمضادات الملاريا التقليدية مثل الكلوركوين والكوينين و على كل في النهاية كان قد تم شفاءه تماماً بعد العلاج بواسطة تغيير الدم وعقار الأرثمسينين.